AIP
KRYS icon

Almanack Investment Partners’s Krystal Biotech KRYS Stock Holding History

Almanack Investment Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-732
Closed -$52K – 717
2022
Q3 		$52K Buy
+732
New +$52.9K 0.01% 259

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Almanack Investment Partners's KRYS Position: Q4 2022 in Review

Almanack Investment Partners sold out of Krystal Biotech (KRYS) in Q4 2022, closing a stake of 732 shares — an estimated $52K sold.

Almanack Investment Partners first reported a position in KRYS in Q3 2022 and held it in 1 quarter. The position peaked at $52K in Q3 2022. 154 funds tracked by Wall St. Rank hold KRYS as of Q4 2022.

  • Almanack Investment Partners reported no remaining Krystal Biotech position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 732 Krystal Biotech shares in Q4 2022, an estimated $52K.
  • Almanack Investment Partners first reported a position in Krystal Biotech in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Krystal Biotech position peaked at $52K in Q3 2022.
  • 154 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.